middle.news
NeuroScientific’s StemSmart™ Shows Promise in Tough Crohn’s Cases
10:00am on Tuesday 13th of January, 2026 AEDT
•
Biotechnology
Read Story
NeuroScientific’s StemSmart™ Shows Promise in Tough Crohn’s Cases
10:00am on Tuesday 13th of January, 2026 AEDT
Key Points
3 of 4 patients achieved significant clinical response with StemSmart™ therapy
1 patient showed partial improvement, with ongoing assessments
Results validate StemSmart™ platform in real-world treatment of severe Crohn’s disease
Phase 2 clinical trials planned for second half of 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE